Related Experiment Video
Updated: Jun 5, 2026
An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
Adipocyte hyperplasia and RMI1 in the treatment of obesity
Akira Suwa1, Takeshi Kurama, Teruhiko Shimokawa
1Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan. akira.suwa@jp.astellas.com
Abstract:
The escalating prevalence of obesity is one of the most pressing health concerns of the modern era, yet existing medicines to combat this global pandemic are disappointingly limited in terms of safety and effectiveness. The inadequacy of currently available therapies for obesity has made new drug development crucial. In the past several decades, however, major progress has been achieved in understanding adipocyte hyperplasia associated with the pathogenesis of obesity, and consequently new potential targets for the medical treatment of obesity have been identified. We primarily review recent progress in the regulation of adipocyte hyperplasia as a novel emerging nontraditional approach. In this minireview, we focus on recQ-mediated genome instability 1 (RMI1), a recently identified novel molecular target for obesity treatment. RMI1-deficient mice have been found to be resistant to high-fat diet- and genetics-related obesity. Expression of this protein is regulated by E2F transcription factors, and recent studies have suggested that RMI1 plays an important role in the control of energy homeostasis during the development of obesity, with a mode of action based on the regulation of adipocyte hyperplasia.
Insights
Obesity is a growing health crisis with few effective treatments. Targeting recQ-mediated genome instability 1 (RMI1) shows promise for obesity treatment by regulating fat cell growth.
Area of Science:
- Biomedical Science
- Molecular Biology
- Metabolic Disorders
Background:
- Obesity is a global health crisis with limited safe and effective treatments.
- Current obesity therapies are inadequate, necessitating novel drug development.
- Understanding adipocyte hyperplasia is key to identifying new obesity treatment targets.
Purpose of the Study:
- To review recent advancements in regulating adipocyte hyperplasia for obesity treatment.
- To highlight recQ-mediated genome instability 1 (RMI1) as a novel molecular target for obesity.
- To explore RMI1's role in energy homeostasis and adipocyte hyperplasia.
Main Methods:
- Review of recent scientific literature on adipocyte hyperplasia and obesity.
- Focus on the molecular target recQ-mediated genome instability 1 (RMI1).
- Analysis of studies involving RMI1-deficient mice and their response to obesity-inducing conditions.
Main Results:
- RMI1-deficient mice exhibit resistance to diet-induced and genetic obesity.
- RMI1 protein expression is regulated by E2F transcription factors.
- RMI1 plays a significant role in controlling energy homeostasis during obesity development.
Conclusions:
- RMI1 is a promising novel target for obesity treatment.
- RMI1's mechanism of action involves regulating adipocyte hyperplasia.
- Targeting RMI1 offers a new therapeutic strategy for combating obesity.
